UCB agrees to acquire Candid Therapeutics in a cross-border biotech deal to bolster its immunology pipeline with next-generation T-cell engager assets
UCB, the global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company focused on autoimmune and inflammatory diseases. The deal expands UCB's capabilities in next-generation biologics, specifically T-cell engagers (TCEs) — a class of bispecific antibodies designed to redirect a patient's own T-cells to destroy disease-causing cells. Candid's lead asset, cizutamig, is a bispecific antibody directed at two targets: BCMA (B-cell maturation antigen) on plasma cells and CD3 on T-cells. It is currently progressing through multiple Phase 1 clinical studies across various autoimmune diseases and is positioned as a potential best-in-class asset in the BCMA TCE space for autoimmune indications. The acquisition directly supports UCB's stated strategy of targeting severe immune-mediated diseases in areas of high unmet medical need. The company frames this as part of its inorganic growth strategy — that is, growing through acquisitions rather than relying solely on internal drug discovery. No deal value has been disclosed in the sources. The transaction represents a wider trend of large-cap pharmaceutical and biopharma companies acquiring clinical-stage platforms to replenish pipelines ahead of patent cliffs and to access emerging modalities such as TCEs. For City lawyers, cross-border pharma M&A of this type typically activates SPA (share purchase agreement) drafting, regulatory merger control filings, IP due diligence on patent portfolios, and clinical trial asset transfer workstreams.
Why this matters
Pharmaceutical M&A involving clinical-stage targets generates intensive transactional legal work across multiple practice areas: the SPA will contain complex milestone and earn-out provisions tied to clinical trial outcomes, requiring careful drafting of the conditions precedent (the steps that must be completed before the deal closes). IP due diligence on the patent estate protecting cizutamig and related TCE platform will be extensive, given that the asset's commercial value depends entirely on exclusivity. Merger control filings will likely be required in multiple jurisdictions given UCB's global footprint. The 'no disclosed value' structure is common in clinical-stage biotech deals, where headline consideration is split between upfront payment and regulatory or commercial milestones — this creates further drafting complexity around milestone definition and payment triggers.
On the Ground
A trainee on this matter would be indexing the due diligence report covering Candid's IP portfolio and clinical trial agreements, drafting the conditions precedent checklist tracking regulatory and antitrust approvals, and preparing SPA schedules covering the target's material contracts and outstanding litigation.
Interview prep
Soundbite
Earn-out structures in pharma M&A live or die on how precisely clinical milestones are defined in the SPA.
Question you might get
“What legal risks arise from a pharmaceutical acquisition where most of the deal value sits in future milestone payments tied to clinical trial outcomes?”
Full answer
UCB has agreed to acquire Candid Therapeutics, a clinical-stage biotech developing T-cell engagers for autoimmune disease, in a deal designed to strengthen UCB's immunology pipeline. For law firms, clinical-stage pharma acquisitions are among the most legally complex M&A mandates: the SPA must translate clinical and regulatory events — Phase 2 readouts, FDA approvals, commercial launches — into precise, enforceable milestone triggers. This fits the broader trend of large pharma companies acquiring emerging modality platforms to offset pipeline gaps rather than building them organically. The absence of a disclosed deal value suggests a substantial earn-out component, which will sustain advisory work long after closing as milestone disputes arise.
My notes
saved